NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.
NCI Cancer Bulletin publicized board’s resignation over liability concerns.
NCI reassigns project officer John Gohagan.
Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.
Kansas Cancer Institute gets $15 million pledge, is renamed, and hires a new director in effort to win NCI center grant.
Funding opportunities listed.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field









